Objectives/Hypothesis: Idiopathic subglottic stenosis (iSGS) is a rare and devastating extrathoracic obstruction involving the lower laryngeal and upper tracheal airway. It arises without known antecedent injury or associated disease process. Persistent mucosal inflammation and a localized fibrotic response are hallmarks of the disease. Despite the initial clinical description of iSGS more than 40 year ago, there have been no substantive investigations into the pathogenesis of this enigmatic and progressive airway obstruction. In these studies, we present the initial characterization of the molecular pathogenesis underlying the fibrosing phenotype of iSGS.
INTRODUCTION
Laryngotracheal stenosis is a devastating, fixed extrathoracic obstruction that can occur without known antecedent injury (idiopathic subglottic stenosis [iSGS] ). It also can accompany collagen vascular disease e.g., Wegener's granulomatosis) or follow iatrogenic injury (e.g., endotracheal intubation; immunoglobulin-like transcripts [iatrogenic laryngotracheal stenosis (iLTS)]). Idiopathic subglottic stenosis is clinically rare and histopathologically distinct and manifests as persistent mucosal inflammation with a localized fibrotic tissue response. Despite the initial clinical description of iSGS more than 40 years ago, 1 there have been no substantive investigations into the pathogenesis of this enigmatic and progressive airway obstruction. A recent international multicenter study (North American Airway Collaborative RP-01) 2 demonstrated that the iSGS population is strikingly homogeneous (female, Caucasian, and perimenopausal). Classically, iSGS patients present with unexplained prodromal dyspnea (often extending several months or years prior to presentation). Physical examination demonstrates a short (1-3 cm) concentric stenosis centered at the cricoid cartilage (below the level of the vocal cords). Patients require urgent treatment to reestablish airway patency. Unfortunately, surgical interventions are rarely definitive and many iSGS patients require several treatments. 3 High-disease recidivism is common and associated with disabling side effects in breathing and voicing that significantly affect the patient's quality of life. 4 
MATERIALS AND METHODS
Histologically, the majority of iSGS cases show extensive fibrosis with relatively normal cartilage. 5 Diverse diseases in divergent organ systems are associated with fibrosis, suggesting common pathogenic pathways. 6 The process is defined by excessive accumulation of fibrous connective tissue components of the extracellular matrix (ECM) (i.e., collagen and fibronectin) in inflamed tissue. 7 Despite an increasing understanding of the pathogenic mechanisms of fibrosis in alternate organ systems, there have been no studies in iSGS that delineate the biologic process that drives the characteristic tissue remodeling in the subglottis.
We utilized specialized histologic staining to anatomically define the aberrant tissue remodeling in iSGS. We then employed electron microscopy to probe these changes in greater structural detail. Real-time polymerase chain reaction (RT-PCR) was preformed to verify the molecular underpinnings to the observed ultrastructural fibrotic changes in iSGS. Because persistent inflammation is linked to fibrosis, 6 and inflammation in the tracheal scar is a cardinal feature of iSGS, we then investigated central immunologic mechanisms involved in inflammation that we hypothesize promote the fibrosing phenotype of this disease.
Experimental Procedures
This study was performed in accordance with the Declaration of Helsinki, Good Clinical Practice, and was approved by the Institutional Review Board at Vanderbilt University Medical Center, Nashville, Tennessee #140429.
Patients
Twenty iSGS, 20 iLTS, and 23 normal controls were utilized for experiments. Each iSGS and iLTS diagnosis was confirmed using previously described clinical and serologic criteria. 8 Subglottic scar was the source of all specimens from the iSGS and iLTS patients. The control population consisted of patients without known subglottic pathology or systemic infection.
Transmission Electron Microscopy
Human tissue samples from cases and controls were harvested in the operating room and immediately fixed with chilled buffer (50 mM sodium cacodylate [pH 7.4]) containing 2.5% glutaraldehyde and 2.0% paraformaldehyde and placed in 48C overnight. The samples were then prepared as previously described. 9 Samples analyzed with an FEI T-12 transmission electron microscope (FEI, Hillsboro, Oregon) equipped with a side-mounted digital camera.
Immunohistochemistry
Staining. The 3-lm paraffin embedded sections of iSGS or iLTS airway stenosis that were derived from patients who underwent open tracheal or cricotracheal resection were obtained from the Vanderbilt University Medical Center Airway Pathology Archive. Normal subglottis from healthy controls was obtained from US Biomax Inc. (Rockville, MD; product# RS321). Specimens were deparaffinized, and a heat-induced antigen retrieval was performed for 20 minutes. Slides were placed in a DakoCytomation Biotin-Blocking System (DAKO, Carpinteria, CA; Ref# X0590) for 15 minutes in each solution. Slides were then placed in a Protein Block (DAKO; Ref# X0909) for 10 minutes. Slides were incubated with anti-IL-17A (R&D Systems, Minneapolis, MN; Cat. AF-317-NA) for 1 hour at a 1:200 dilution and followed by a biotinylated anti-goat IgG (Vector Laboratories, Inc., Burlingame, CA; Cat. BA-5000) for 30 minutes at a 1:200 dilution. The Bond Polymer Refine detection system (Leica Biosystems Inc., Buffalo Grove, IL) was used for visualization. Slides were then dehydrated, cleared, and coverslipped.
Quantification. Immunostained slides were imaged on a Leica SCN400 Slide Scanner (Leica Biosystems). Slides were imaged at 203 magnification to a resolution of 0.5 lm/pixel. Cells were identified utilizing standard Ariol analysis scripts (Leica Biostyems Inc. Buffalo Grove, IL.). Upper and lower thresholds for color, saturation, intensity, size, roundness, and axis length were set for both blue hematoxylin staining of nuclei and for brown 3,3 0 -diaminobenzidine (DAB) reaction products. Thus, brown (DAB) positive cells can be distinguished from blue (hematoxylin only) negative cells.
Quantitative Polymerase Chain Reaction Profiling of Respiratory Epithelial Immune Activation
Following mechanical digestion of surgical biopsy specimens, mRNA was extracted with the RNAeasy extraction kit (Qiagen, Valencia, CA) according to the manufacturer's instructions. Healthy control tracheal mRNA was obtained from 23 pooled donors (Clontech Laboratories, Inc., Mountain View, CA ; cat# 636127). 10 The RNA concentration and quality were confirmed using the Bioanalyzer 2100 system (Agilent, Santa Clara, CA). Complementary DNA was transcribed using established reagents according to manufacturer's instructions. The human innate and adaptive immune response quantitative polymerase chain reaction (qPCR) array (Qiagen) was utilized as per manufacturer's instructions in a StepOnePlus instrument (Applied Bioystems, Foster City, CA). Expression analysis was preformed using PCR analysis software employing the 2-DDCt method, as previously described 11 (Qiagen, Valencia, CA.).
Flow Cytometry
Surgical specimens of tracheal scar were digested, and single-cell suspensions were rested overnight in RPMI 1640 medium supplemented with 10% Fetal Calf Serum (FCS). 5 3 10 5 cells were activated with phorbol 12-myristate 13-acetate (PMA) and ionomycin at 378C under 5% CO2 for 30 minutes before addition of BD GolgiStop (BD Biosciences, San Jose, CA). After 4 hours of stimulation, the cells were harvested and washed for surface staining to CD3, TCR cd (BD Biosciences). Cells were then washed, fixed, and permeabilized using a Fix & Perm Kit (BD Biosciences) according to the manufacturer's instructions. Intracellular antibodies to IL-17A were added at 48C for 45 minutes. Cells were washed and analyzed via flow cytometry. For the gating strategy, lymphocytes were gated by FSC/SSC. Next, doublets were gated out, and then dead cells, and then cells were analyzed for CD3 and SSC. CD31 cells were gated and subsequently analyzed for cd TCR and IL-17A expression. All flow cytometry experiments were acquired with a LSR-II flow cytometer (BD Biosciences). Analysis was performed using FlowJo, LLC software (FlowJo, LLC, Ashland, OR). A minimum of 200,000 events was acquired for each sample.
Statistical Analysis
Statistical significance was set at P value less than 0.05 and a mean difference equal to or greater than two-fold change in expression levels. Normal distribution of the variables was tested using the Shapiro-Wilk test. Differences between the x and y groups were determined using the Kruskal-Wallis and Mann-Whitney tests for normal and nonnormal distributions, respectively. Data were expressed as median 6 SD for nonnormal distributed variables. All statistical analyses were performed with Prism version 6.0 software (GraphPad Software Inc., La Jolla, CA).
RESULTS

Idiopathic Subglottic Stenosis Anatomic, Physiologic, and Histologic Characteristics
Idiopathic subglottic stenosis is defined by classic anatomic, physiologic, and histologic characteristics. All iSGS patients develop airway stenosis below the vocal cords in the region where the larynx transitions to the trachea (Supp. Fig. S1A, S1B ). This luminal scar produces impairment in airflow manifesting as a flow-volume loop finding of fixed extrathoracic obstruction on pulmonary function testing (Supp. Fig. S1C) . Histologically, the airway mucosa at the site of scar is frequently characterized by an intact basement membrane (Fig. 1A. ) with pronounced subepithelial fibrosis (Fig. 1B) . Transmission electron microscopy demonstrates the disordered arrangement of collagen bundles (Fig. 1C) driven by abundant tissue fibroblasts (Fig. 1D ). Molecular analysis of areas of subglottic fibrotic remodeling shows increased mRNA expression of established extracellular matrix constituents type I collagen, type III collagen, and fibronectin (Fig. 1E) . These results were confirmed at the protein level with histologic analysis (data not shown). 
Host Inflammatory Response
Affected tracheal mucosa in iSGS patients consistently demonstrates acute and chronic inflammation (Supp. Fig. S2A) , with an infiltration of CD31 T lymphocytes (Supp. Fig. S2B ). To delineate the host mucosal immune response in iSGS, we utilized a qPCR array consisting of 84 unique inflammatory genes (Qiagen) to compare gene expression in the tracheal mucosa of 10 iSGS patients with 23 healthy controls (Supp. Fig. S3 ). mRNA expression analysis showed the IL-17A to be the most significantly up-regulated gene in iSGS mucosa compared to healthy control trachea (P < 0.005) (Fig.  2A) . The upstream driver of the IL-17A pathway, IL-23 demonstrated significant up-regulated in iSGS; and IL1b showed a trend toward increased expression, suggesting a potential role for the IL-17A/IL-23 pathway in the pathogenesis of inflammation and fibrosis seen in iSGS.
Increased IL-17A expression within the mucosa of iSGS scar was confirmed at the protein level utilizing immunohistochemistry. As seen in the representative images (Fig. 2B) and quantified digitally by computerized algorithm, the mean number of IL-17A positive cells in iSGS tracheal mucosal biopsy specimens was 30.3% compared to 8.1% in iLTS (patients who developed their tracheal injury following prolonged endotracheal intubation in an intensive care unit for medical illness) and 1.3% in normal healthy tracheal mucosa (P < 0.001).
In order to localize the cellular source of mucosal IL-17A, we utilized flow cytometry with intracellular cytokine staining on cells obtained from surgical specimens containing subglottic mucosal scar tissue from three iSGS patients. After digestion and nonspecific stimulation, Gr1 1 neutrophils, CD3
, and CD3 1 cd TCR 1 positive cells were assessed for intracellular IL-17A levels. In iSGS, 87% to 97% of IL-17A-expressing cells were identified as cd TCR 1 (Fig. 2C) .
DISCUSSION
Although the clinical description of iSGS is more than 40 years old, 1 our study represents the first molecular characterization of the pathogenic tissue remodeling in this rare disorder. The in-depth histologic, electron microscopic, and molecular techniques utilized in this study confirm an abundance of ECM components in the subglottic scar in iSGS patients. This evidence strongly supports a central role for the pathogenic process of fibrosis in the tissue remodeling seen in iSGS. Furthermore, our studies highlight the inflammatory nature of the airway scar in iSGS and begin to characterize the immunologic mechanisms driving the observed inflammation. Whereas acute and chronic inflammation are characteristic clinical findings in the subglottic scar of iSGS patients, our study begins to dissect the molecular circuits involved. Our data reveals a significant up-regulation of the IL-17A/IL-23 inflammatory axis in iSGS airway scar. Although crucial in protecting the host from invasion by many types of pathogens, dysregulated IL-17A production can drive chronic inflammation, [12] [13] [14] with subsequent tissue damage and fibrinogenesis. 15, 16 IL-17A is also specifically implicated in many inflammatory lung diseases, including asthma, 12, 17 , cystic fibrosis, 13 and chronic obstructive pulmonary disease. seen after pulmonary transplant. However, the mechanisms governing IL-17A-mediated fibrosis in pulmonary fibroinflammatory disease remain poorly understood. The elevated inflammatory IL-17A expression that we observed in the subglottis may directly influence fibroblasts in iSGS leading to pathologic tissue fibrosis, 18 although the precise molecular mechanism linking IL-17A to fibrogenesis merits future study.
Given the rarity of iSGS, our results will require confirmation in larger cohorts pooled from multiple institutions. Furthermore, although we provide molecular characterization of the fibroinflammatory phenotype as mechanistic support for the hypothesis that a conserved and consistent biologic process drives a singular disease, the explanation for why involvement is nearly universally restricted to adult Caucasian women remains opaque. The role of genetics and the influence of estrogen on host inflammation and fibrosis are novel questions that demand future studies.
The inciting event behind the dramatic increase in IL-17A is also unclear. However, given the established role of cd T cell IL-17A in host defense against pathogens at mucosal barriers, 19 as well as an emerging understanding of disrupted microbiota in other chronic inflammatory mucosal disease, [20] [21] [22] [23] [24] [25] [26] our results raise important questions about a potential role for pathogens in the etiopathogenesis of iSGS. Given the advent of robust culture-independent techniques, 27,28 future studies may be able to define a role for bacteria, fungus, or virus in disease initiation, progression, or recurrence.
Alternatively, a role for IL-17A has been increasingly recognized in autoimmune collagen vascular disorders such as rheumatoid arthritis, 18 systemic lupus erythematosus, 29 and granulomatosis with polyangiitis (GPA, i.e., Wegener's granulomatosis). 30, 31 In these diseases, increased circulating IL-17A 1 cells have been closely associated with tissue inflammation and overall disease activity. Our findings may offer support for the phenotypic similarity between iSGS and GPA observed clinically. However, future study will be important to full clarify the molecular overlap 31 between the diseases.
CONCLUSION
Our results advance the understanding of iSGS by developing the concept that this disease results from aberrant mucosal immune activation in the large airway rather than simply idiopathic extracellular matrix deposition. Most critically, demonstration of IL-23/IL-17A pathway activation offers a novel approach for therapeutic intervention in iSGS patients. Several established drugs limit IL-17A production 32 or neutralize its effects. 33, 34 Future insight into the molecular mechanism linking IL-17A to canonical pathways of tissue fibrosis may reveal additional pathways amenable to directed targeting. Thus, the implications this work may extend beyond the confines of iSGS to impact other fibrotic diseases driven by pathogenic inflammation.
Acknowledgment
This was a North American Airway Collaborative TS-03 study. 
AUTHOR CONTRIBUTIONS
